Skip to main content
SpringerLink
Log in

Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders

  • Letter to the editor
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF (2011) Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 117(12):2697–2702

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Breccia M, Voso MT, Maurillo L, Niscola P, Fianchi L, Aloe Spiriti MA, Buccisano F, Latagliata R, Pelliccia S, Fenu S, Tendas A, Alimena G (2014) Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. Am J Hematol 89(5):565

  3. Tendas A, Cupelli L, Siniscalchi A, Scaramucci L, Giovannini M, Dentamaro T, Perrotti AP, Caravita T, de Fabritiis P, Niscola P (2014) Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach. Meditter J Hematol Infect Dis 6(1):e2014020

    Article  Google Scholar 

  4. Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellström-Lindberg E, Santini V, List AF, Gore SD, Backstrom J, McKenzie D, Beach CL (2010) Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 76(3):218–227

    Article  PubMed Central  PubMed  Google Scholar 

  5. Niscola P, Palombi M, Trawinska MM, Tendas A, Giovannini M, Scaramucci L, Perrotti A, de Fabritiis P (2013) Managing myelodysplastic syndromes in very old patients: a teaching case report. Clin Interv Aging 8:391–394

    Article  PubMed Central  PubMed  Google Scholar 

  6. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, McIntyre HJ, Fernando IJ, Backstrom JT, Beach CL (2009) Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27(11):1850–1856

    Article  CAS  PubMed  Google Scholar 

  7. Voso MT, Fianchi L, Criscuolo M, Greco M, D’Alo F, Hohaus S, Pagano L, Leone G (2012) Azacitidine in a patient with myelodysplastic syndrome: impact of switching from a 5-day to the approved 7-day dosing schedule. Leuk Res 36(1):e15–e17

    Article  CAS  PubMed  Google Scholar 

  8. Pierdomenico F, Esteves S, Almeida A (2013) Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS. Ann Hematol 92(9):1201–1206

    Article  CAS  PubMed  Google Scholar 

  9. Voso MT, Breccia M, Lunghi M, Poloni A, Niscola P, Finelli C, Bari A, Musto P, Zambello R, Fianchi L, Alimena G, Leone G (2013) Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol 90(4):345–348

    Article  PubMed  Google Scholar 

  10. Niscola P, Tendas A, Giovannini M, Cupelli L, Trawinska MM, Palombi M, Scaramucci L, Brunetti GA, Perrotti A, Neri B, Efficace F, Cartoni C, de Fabritiis P, Mandelli F (2012) Transfusions at home in patients with myelodysplastic syndromes. Leuk Res 36(6):684–688

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Hematology Unit and Department of Pharmacy Services, Sant’Eugenio Hospital, Rome, Italy

    Andrea Tendas, Maria Felicita Lissia, Daniela Piccioni, Liliana Tirimbelli, Laura Scaramucci, Marco Giovannini, Teresa Dentamaro, Alessio Perrotti, Paolo de Fabritiis & Pasquale Niscola

  2. Hematology Division, Sant’Eugenio Hospital, Piazzale dell’Umanesimo, 10, 00144, Rome, Italy

    Pasquale Niscola

Authors
  1. Andrea Tendas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Felicita Lissia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniela Piccioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liliana Tirimbelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laura Scaramucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marco Giovannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Teresa Dentamaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alessio Perrotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Paolo de Fabritiis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pasquale Niscola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pasquale Niscola.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tendas, A., Lissia, M.F., Piccioni, D. et al. Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders. Support Care Cancer 23, 303–305 (2015). https://doi.org/10.1007/s00520-014-2502-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-014-2502-y

Keywords

Search

Navigation